| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
IVERIC bio Inc (NASDAQ: ISEE)
ISEE Technical Analysis
5
| As on 9th Jun 2023 ISEE STOCK Price closed @ 38.12 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 14.84 & Strong Buy for SHORT-TERM with Stoploss of 14.76 we also expect STOCK to react on Following IMPORTANT LEVELS. |
ISEESTOCK Price
| Open | 38.28 | Change | Price | % |
| High | 38.42 | 1 Day | -0.09 | -0.24 |
| Low | 38.00 | 1 Week | 0.37 | 0.98 |
| Close | 38.12 | 1 Month | 5.81 | 17.98 |
| Volume | 2958000 | 1 Year | 22.02 | 136.77 |
| 52 Week High 38.90 | 52 Week Low 9.12 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| ISEE Daily Charts |
ISEE Intraday Charts |
Whats New @ Bazaartrend |
ISEE Free Analysis |
|
|
ISEE Important Levels Intraday
| RESISTANCE | 38.93 |
| RESISTANCE | 38.67 |
| RESISTANCE | 38.51 |
| RESISTANCE | 38.35 |
| SUPPORT | 37.89 |
| SUPPORT | 37.73 |
| SUPPORT | 37.57 |
| SUPPORT | 37.31 |
ISEE Forecast May 2024
| 4th UP Forecast | 47.81 |
| 3rd UP Forecast | 44.7 |
| 2nd UP Forecast | 42.78 |
| 1st UP Forecast | 40.86 |
| 1st DOWN Forecast | 35.38 |
| 2nd DOWN Forecast | 33.46 |
| 3rd DOWN Forecast | 31.54 |
| 4th DOWN Forecast | 28.43 |
ISEE Weekly Forecast
| 4th UP Forecast | 42.74 |
| 3rd UP Forecast | 41.26 |
| 2nd UP Forecast | 40.34 |
| 1st UP Forecast | 39.43 |
| 1st DOWN Forecast | 36.81 |
| 2nd DOWN Forecast | 35.90 |
| 3rd DOWN Forecast | 34.98 |
| 4th DOWN Forecast | 33.50 |
ISEE Forecast2024
| 4th UP Forecast | 96.2 |
| 3rd UP Forecast | 77.57 |
| 2nd UP Forecast | 66.06 |
| 1st UP Forecast | 54.55 |
| 1st DOWN Forecast | 21.69 |
| 2nd DOWN Forecast | 10.18 |
| 3rd DOWN Forecast | -1.33 |
| 4th DOWN Forecast | -19.96 |
IVERIC bio Inc ( NASDAQ USA Symbol : ISEE )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
ISEE Business Profile
IVERIC bio, Inc., a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company is developing Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). It is also developing STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of leber congenital amaurosis type 10 (LCA10) and autosomal recessive stargardt disease (STGD1); IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases; IC-100 for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa; and IC-200 for the treatment of IRDs associated with mutations in the BEST1 gene. In addition, the company develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of Zimura monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of Zimura administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. Its discovery and research programs include miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related IRDs. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. IVERIC bio, Inc. was incorporated in 2007 and is based in New York, New York. Address: Five Penn Plaza, New York, NY, United States, 10001
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service